We assessed the in vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin (QD) against a contemporary challenge panel of 88 staphylococcal and 90 enterococcal isolates. The staphylococci selected included vancomycin-intermediate Staphylococcus aureus (VISA), methicillin-resistant S. aureus, and coagulasenegative staphylococci. Enterococcal isolates included vancomycin-resistant Enterococcus faecium (VREF) containing either vanA, vanB1, or vanD. The MICs of daptomycin, linezolid, and QD were determined using commercial broth microdilution panels. All three VISA isolates were susceptible to daptomycin, linezolid, and QD. QD was the most active agent against staphylococcal isolates (MIC 50 # 0.5 mg/ml and MIC 90 5 1 mg/ml), including those with decreased susceptibility to vancomycin. QD was also the most active agent against VREF (MIC 90 # 0.5 mg/ml). No differences were seen for susceptibility of vanA, vanB1, and vanD VREF strains for daptomycin, linezolid, or QD. Daptomycin was the most effective against E. faecalis. On the basis of manufacturer-suggested interpretive criteria, 92% of isolates were susceptible (MIC 90 5 4 mg/ml). All isolates tested were susceptible to at least one antimicrobial agent for which interpretive criteria have been defined. Population analysis of three S. aureus isolates for which the daptomycin MICs were 8 mg/ml showed a pattern of homogeneous resistance. 389 
INTRODUCTION D
APTOMYCIN, LINEZOLID , AND QUINUPRISTIN -DALFOPRISTIN (QD) are newer antimicrobial agents that are active against gram-positive cocci. 14, 21 Daptomycin, a lipopeptide, has a spectrum of activity very similar to vancomycin and is active against aerobic and anaerobic Gram-positive organisms, including methicillin-susceptible and -resistant staphylococci and enterococci. 2, 9, 21, 23, 25, 27 Linezolid, an oxazolidinone, has excellent activity against most staphylococci, including methicillinresistant strains, and multidrug-resistant enterococci, 3, 21 although resistance has begun to emerge. 13, 18, 19 QD, a streptogramin, has bactericidal activity against methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), and coagulase-negative staphylococci (CoNS). 6, 21 QD inhibits both vancomycin-susceptible and vancomycin-resistant strains of Enterococcus faecium. 6 We performed susceptibility testing of a challenge panel of contemporary staphylococci and enterococci against daptomycin, linezolid, and QD to assess and compare the in vitro activity of these agents.
MATERIALS AND METHODS

Bacterial isolates
A total of 178 staphylococcal and enterococcal isolates were obtained from the Centers for Disease Control and Prevention (CDC) and Project ICARE (Intensive Care Antimicrobial Resistance Epidemiology) culture collections. 1, 8 These isolates were collected from 72 hospitals between 1996 and 2001 from 24 U.S. states located in diverse geographical regions and five other countries. Upon receipt, all isolates were subcultured twice onto blood agar plates (Remel, Inc., Lenexa, KS) and then frozen at 280°C in sterile defibrinated sheep blood (Remel, Inc.) until needed. To minimize the inclusion of duplicate staphylococcal isolates, patterns of susceptibility to previously tested antimicrobials were examined for all isolates before including them in the challenge panel. Pulsed-field gel electrophoresis (PFGE) was performed on all enterococci used in the study, and duplicate isolates were not included in the challenge panel (data not shown).
The 
Broth microdilution testing
Testing was performed using custom broth microdilution MIC plates prepared by Trek Diagnostics (Westlake, OH) according to the manufacturer's instructions. MIC plates included daptomycin (with calcium supplementation to 50 mg/L), linezolid, oxacillin, QD, vancomycin, a positive-growth control well, and a sterility well. Plates were stored at 280°C until used and were thawed completely at room temperature just prior to inoculation.
Interpretive criteria (susceptible, intermediate, resistant) for linezolid, oxacillin, QD, and vancomycin were based on National Committee for Clinical Laboratory Standards (NCCLS) criteria. 17 Interpretive criteria for daptomycin are not available. The MIC at which 50% of the isolates were inhibited (MIC 50 ) and the MIC at which 90% of the isolates were inhibited (MIC 90 ) were determined for daptomycin, linezolid, QD, and vancomycin. Three quality-control organisms were tested during each run: E. faecalis ATCC 29212, S. aureus ATCC 29213, and E. faecalis ATCC 51299. 15 
Population analysis
Three MRSA isolates for which daptomycin MICs were 8 mg/ml were subjected to population analysis as previously described. 11, 23 Initial quality-control testing of the lot of Mueller-Hinton agar (MHA) (Difco, Sparks, MD) was performed to determine whether calcium supplementation was necessary. Plates were prepared according to the manufacturer's instructions. One plate was incubated at 35°C for 24 hr to check for sterility. A second plate was used to check the pH of the prepared MHA (acceptable range 7.3 6 0.1). Disk diffusion was performed on a third plate according to NCCLS guidelines using S. aureus ATCC 25923 and a daptomycin disk (acceptable range 18-23 mm). 16 A fourth plate was inoculated with Pseudomonas aeruginosa ATCC 27853 and incubated with a gentamicin disk. 16 Quality control results for the MHA lot tested were in range for both antimicrobial agents; therefore, no additional calcium supplementation was undertaken. These plates prepared in house were supplemented with daptomycin (Cubist Pharmaceuticals, Lexington, MA) in doubling concentrations ranging from 0.5 to 16 mg/ml. The daptomycin stock solution was prepared according to NCCLS guidelines. 15 Each test isolate and one control isolate (S. aureus ATCC 29213) were suspended in Mueller-Hinton broth (MHB) (BBL, Cockeysville, MD) to an optical density equivalent to a 0.5 McFarland standard. The inoculum was serially diluted in sterile saline, and 100 ml of a 10 21 , 10 25 and 10 26 dilution was plated in duplicate onto plain MHA plates to determine the starting population. The plates were inverted and incubated at 35°C for 18-24 hr. Four 10-ml droplets of undiluted culture and four 10-ml droplets of serial 10-fold dilutions were inoculated onto one daptomycin-containing MHA plate at each concentration. The plates were inverted and incubated at 35°C for 24-48 hr. This procedure was performed four times with reproducible results. The average number of colony-forming units (CFU)/ml for each dilution was determined. CFUs were plotted using a logarithmic scale.
RESULTS
Broth microdilution
Daptomycin was more active against vancomycin-susceptible S. aureus (defined as isolates for which vancomycin MICs were #2 mg/ml) than against those isolates with decreased susceptibility to vancomycin (defined as isolates for which the vancomycin MIC 5 4 mg/ml) ( Table 1 ). The daptomycin MIC 50 and MIC 90 for vancomycin-susceptible S. aureus were 0.5 mg/ml and 1 mg/ml, respectively, whereas for isolates with decreased susceptibility to vancomycin the MIC 50 was 2 mg/ml and the MIC 90 was 8 mg/ml. The daptomycin MICs for the three VISA isolates were 1 or 2 mg/ml. For CoNS isolates, daptomycin was again more active against vancomycin-susceptible isolates (MIC 50 and MIC 90 values of 0.5 mg/ml and 1 mg/ml) than against isolates with decreased susceptibility to vancomycin (MIC 50 and MIC 90 , values 1 mg/ml and 4 mg/ml). The three S. aureus and two CoNS isolates for which the daptomycin MICs were 8 mg/ml and 4 mg/ml, respectively, remained susceptible to linezolid and QD. The daptomycin MIC 50 and MIC 90 values for all 90 enterococci were 2-4 mg/ml and 8 mg/ml, respectively; 16 (25%) VREF isolates showed daptomycin MICs of 8 mg/ml.
For one S. aureus isolate, the linezolid MC was 8 mg/ml (which is undefined according to NCCLS interpretive criteria), but the isolate remained susceptible to vancomycin and daptomycin (Table 1 ). All VISA isolates were susceptible to linezolid (MIC 5 2 mg/ml). The MIC 50 and MIC 90 values of linezolid for all staphylococci included in the challenge panel were, respectively, 2 mg/ml and 4 mg/ml for S. aureus and 2 mg/ml and 2 mg/ml for CoNS. Overall, 87 (99%) staphylococcal isolates were susceptible to linezolid. For VREF, only 32 (51%) isolates were susceptible to linezolid (MIC # 2 mg/ml). Three (23%) E. faecalis isolates yielded MICs in the intermediate range for linezolid (MIC 5 4 mg/ml); all were vanB-containing isolates, two of which were obtained from the same hospital, although during different time periods and with different strain typing profiles. Overall, QD showed the best activity against all staphylococcal isolates included in the challenge panel with MIC 50 # 0.5 mg/ml and MIC 90 5 1 mg/ml (Table  1) . One MRSA isolate gave intermediate results for QD (MIC 5 2 mg/ml). This same isolate was nonsusceptible to linezolid (MIC 5 8 mg/ml), but was susceptible to both daptomycin and vancomycin. Eighty-seven (99%) staphylococcal isolates were susceptible to QD. QD showed the best activity against VREF; all isolates were susceptible to this agent. QD was not active against E. faecalis (MIC 90 5 16 mg/ml).
Population analysis
The three S. aureus isolates for which the daptomycin MICs were 8 mg/ml by broth microdilution were isolated in 1997, 1999, and 2000 in three geographically distinct states. Two isolates (803 and 473) grew readily on MHA plates containing 8 mg/ml of daptomycin; the third (377) grew at 4 mg/ml. At a concentration of 8 mg/ml, plates inoculated with isolates 803 and 473 averaged 1 3 10 7 CFUs each, while the average for isolate 377 on plates with 4 mg/ml was 2 3 10 7 CFUs. None of the isolates grew at a daptomycin concentration of 16 mg/ml. For all three isolates, the subpopulations resistant to daptomycin show a pattern of homogeneous resistance (Fig. 1). 
DISCUSSION
Daptomycin, linezolid, and QD were active against this challenge panel of Gram-positive organisms, including staphylococci with decreased susceptibility to vancomycin and VRE with a variety of vancomycin resistance mechanisms. All staphylococcal and enterococcal isolates tested in the challenge panel were susceptible to at least one drug for which categorical breakpoints have been defined.
The antibacterial activity of daptomycin is highly dependent on the calcium concentration of the testing medium. Calcium supplementation of MHB from the normal 25 mg/L to 50 mg/L enhances the activity of daptomycin two-to four-fold for many bacterial species. 2, 25 The levels of daptomycin used for in vitro testing are similar to physiological conditions in humans (47-52 mg/L free calcium). 10 In the study by Barry et al., 2 the enhanced activity with calcium supplementation did not have a dramatic TESTING DAPTOMYCIN, LINEZOLID, AND QUINUPRISTIN-DALFOPRISTIN 391 effect on staphylococci, i.e., the MIC 50 and MIC 90 values remained below 2 mg/ml, which several investigators have proposed as the susceptible breakpoint for daptomycin. 9, 27 However, with calcium supplementation the daptomycin MIC 50 and MIC 90 values for E. faecalis in the Barry study fell from 4 to 1 and 8 to 2 mg/ml, respectively, and MIC 90 values for E. faecium were 4 mg/ml. Thus, if breakpoints of #2 mg/ml (susceptible), 4 mg/ml (intermediate), and $8 mg/ml (resistant) proposed by Fuchs et al. 9 are accepted by NCCLS, laboratories testing organisms in standard MHB as opposed to calcium-supplemented MHB would likely report falsely resistant results (i.e, major errors) routinely for enterococci. Our results for vancomycin-susceptible S. aureus and CoNS using calcium-supplemented broth were consistent with the MIC results of Barry et al. 2 and Snydman et al. 25 However, among isolates of staphylococci with decreased susceptibility to vancomycin, we noted three isolates of S. aureus for which the daptomycin MICs were 8 mg/ml. Our results differ from those of Rybak et al., 20 who reported lower daptomycin MIC 50 and MIC 90 values for vancomycin-susceptible S. aureus strains.
Our studies suggest a possible link between the mechanisms of reduced susceptibility to vancomycin and daptomycin. However, unlike the population analysis results presented by Silverman et al., 23 our population studies showed homogeneous rather than heterogeneous daptomycin resistance. Our results may well represent a novel mechanism of decreased susceptibility to daptomycin when compared to results for strains tested by Silverman and colleagues because we verified that the calcium concentration in the MHA was acceptable prior to testing, and since low calcium content appears to have little effect on testing staphylococci. 2 Since our disk diffusion results were within the range defined for quality control, we assume that the agar media contained sufficient calcium for testing. However, the discrepancy between the broth microdilution MIC and the agar dilution MIC for isolate 377 may reflect the varying concentrations of calcium ions between the two media. This problem associated with the varying concentrations of calcium in MHA and broth may plague further studies with daptomycin.
For linezolid and QD, no difference in susceptibility was noted among the S. aureus isolates with varying susceptibilities to vancomycin. Our MIC results for enterococci and linezolid were consistent with other studies. 3, 21, 25 Linezolid was active against S. aureus, CoNS, and a variety of enterococci. Eliopoulos et al., 6 who tested 875 isolates of E. faecium collected from around the United States, reported QD MICs up to 32 mg/ml and noted little difference in the QD MIC results between vanA-and vanB-containing strains. Strains for which the QD MICs were $4 mg/ml were all aac69-li positive in their study. These latter isolates were obtained from patients who were treated with QD.
The importance of testing drugs, such as daptomycin, linezolid, and QD, that may be used to treat severe infections due to S. aureus is emphasized by the recent appearance of S. aureus strains resistant to vancomycin (MIC $ 32 mg/ml). 4, 5 These newer antimicrobial agents are likely to become the mainstay for therapy of serious infections when vancomycin resistance becomes prevalent. However, testing daptomycin in the clinical laboratory, because of its need for calcium supplementation, may pose a challenge.
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